Back
Speaker illustration

Mr Christopher Schneider

Graz (Austria)

Presentations

The anti-cancer tyrosine kinase inhibitor sorafenib reduces cardiac contractile force by reducing cardiomyocyte calcium transient amplitude.

Event: ESC Congress 2017

Topic: Cardiotoxicity of drugs

Session: Chronic heart failure (CHF)

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources